Socioeconomic and Treatment Factors Affect Non-Hodgkin Lymphoma Patients’ Survival

Publication
Article
OncologyONCOLOGY Vol 22 No 12
Volume 22
Issue 12

Socioeconomic factors and the type of treatment received have an impact on a non-Hodgkin lymphoma (NHL) patient’s risk of dying.

Socioeconomic factors and the type of treatment received have an impact on a non-Hodgkin lymphoma (NHL) patient’s risk of dying. That is the finding of a new study to be published in the December 1, 2008 issue of Cancer. The study reveals that poorer socioeconomic status increases a patient’s risk of dying, while receiving chemotherapy reduces the risk.

NHL is common in the elderly. Its incidence has been increasing over the past several decades, and Caucasians have higher incidence and death rates related to the disease than patients in other ethnic groups. Newer treatments for NHL have become available in recent years; however, studies have not addressed ethnic disparities in survival as they relate to treatment, diagnosis, socioeconomic status, or other factors.

To investigate the issue, Xianglin Du, md, of the University of Texas School of Public Health in Houston and colleagues analyzed Surveillance, Epidemiology and End Results (SEER)-Medicare linked data for more than 13,000 patients diagnosed at age 65 or older between 1992 and 1999.

Dr. Du and his team analyzed data related to survival, socioeconomic status, treatment (chemotherapy or radiation), tumor factors (stage and type of NHL), the presence of other diseases or conditions, and other characteristics such as age, race, marital status, and geographic area.

The investigators found that receiving chemotherapy was associated with prolonged survival in patients with NHL and that elderly Caucasian patients with NHL were more likely to receive chemotherapy (52.4%) compared with African-Americans (43.2%). Also, poor socioeconomic status was significantly associated with increased risk of mortality, and there were a larger proportion of African-American patients living in poor communities compared with other ethnicities. No significant differences in the risk of death were seen between African-Americans and Caucasians after controlling for factors such as treatment and socioeconomic status.

Related Videos
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.
Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.